As the role of immunotherapies in treating renal cell carcinoma evolves, it can be challenging for practitioners to keep up with emerging data on combination therapy regimens, effective practices for monitoring and managing immune-related adverse events and educating patients to promote informed decision-making.
ACCC’s CME, CNE, and CPE-accredited educational program is designed to provide members of the multidisciplinary care team with knowledge and resources to successfully address the practical issues and barriers associated with the integration of immunotherapies into the treatment of renal cell carcinoma.
The program is presented in two formats: a live, on-site learning workshop and an audio-guided online course.
The following cancer programs have been selected to host live, half-day workshops onsite at their institutions.
Workshops shall feature both didactic presentations and collaborative open discussion with participants and a three-member multidisciplinary expert faculty panel. Topics covered include, but are not limited to, a review of the rationale for using immunotherapies and immunotherapy combinations, optimal sequencing of therapies, patient selection criteria, and monitoring and managing immune-related adverse events in patients with metastatic renal cell carcinoma. Workshops shall also address collateral issues, such as coordination and communication within the multidisciplinary care team, coverage, and reimbursement, and fostering patient education and engagement.
Workshop Faculty Laura Wood, RN, MSN, OCN; Jocelyn Mohs, PharmD, BCOP; Timothy M. Kuzel, MD.
Paula Caryski, President, OSF HealthCare Saint Anthony Medical Center; Dr. Iftekhar Ahmad, Radiation Oncologist; Thelma Baker, Director of Oncology Services.
During the workshop, participants use the Institute for Healthcare Improvement's Plan-Do-Study-Act tool to develop a customized action plan. Workshop sites will report on their progress at 3 and 6 months post-participation.
We recently hosted the ACCC live workshop, "The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma." What a great experience and such a valuable benefit of our ACCC Cancer Program Membership. The three-member multidisciplinary faculty were very knowledgeable. After their educational session, we met for a collaborative quality improvement workshop with the speakers and ACCC onsite staff. They helped us develop a plan to improve our Immuno-oncology management of patients. We will use this workshop to meet our 2020 CoC standard 7.3 (Quality Improvement Initiative).
— Thelma Baker, MSN, RN, OCN, NEA-BC, Director of Oncology Services, OSF HealthCare Saint Anthony Medical Center
This activity is supported by educational grants from Eisai, EMD Serono, and Pfizer.